156 related articles for article (PubMed ID: 37276599)
61. Clinical Utility of Pharmacogenomic Data Collected by a Health-System Biobank to Predict and Prevent Adverse Drug Events.
Shah SN; Gammal RS; Amato MG; Alobaidly M; Reyes DD; Hasan S; Seger DL; Krier JB; Bates DW
Drug Saf; 2021 May; 44(5):601-607. PubMed ID: 33620701
[TBL] [Abstract][Full Text] [Related]
62. Cardiovascular Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics for the Clinical Practitioner.
Sleder AT; Kalus J; Lanfear DE
J Cardiovasc Pharmacol Ther; 2016 Jan; 21(1):20-6. PubMed ID: 26054891
[TBL] [Abstract][Full Text] [Related]
63. The contribution of pharmacogenetics to pharmacovigilance.
Bondon-Guitton E; Despas F; Becquemont L
Therapie; 2016 Apr; 71(2):223-8. PubMed ID: 27080842
[TBL] [Abstract][Full Text] [Related]
64. Falls: the adverse drug reaction of the elderly and the impact of pharmacogenetics.
Just KS; Schneider KL; Schurig M; Stingl JC; Brockmöller J
Pharmacogenomics; 2017 Aug; 18(13):1281-1297. PubMed ID: 28776468
[TBL] [Abstract][Full Text] [Related]
65. Role of Preemptive Genotyping in Preventing Serious Adverse Drug Events in South Korean Patients.
Kim GJ; Lee SY; Park JH; Ryu BY; Kim JH
Drug Saf; 2017 Jan; 40(1):65-80. PubMed ID: 27638658
[TBL] [Abstract][Full Text] [Related]
66. Implementation of pharmacogenomics in product information.
Skvrce NM; Krivokapić S; Božina N
Pharmacogenomics; 2020 May; 21(7):443-448. PubMed ID: 32336208
[No Abstract] [Full Text] [Related]
67. Tailoring of recommendations to reduce serious cutaneous adverse drug reactions: a pharmacogenomics approach.
Tan-Koi WC; Sung C; Chong YY; Lateef A; Pang SM; Vasudevan A; Aw D; Lui NL; Lee SX; Ren EC; Koay ES; Tay YK; Lim YL; Lee HY; Dong D; Loke C; Tan L; Limenta M; Lee EJ; Toh D; Chan CL
Pharmacogenomics; 2017 Jun; 18(9):881-890. PubMed ID: 28594314
[TBL] [Abstract][Full Text] [Related]
68. Pharmacogenomics and drug toxicity.
Nakamura Y
N Engl J Med; 2008 Aug; 359(8):856-8. PubMed ID: 18650508
[No Abstract] [Full Text] [Related]
69. Pharmacogenetics: The right drug for you.
Drew L
Nature; 2016 Sep; 537(7619):S60-2. PubMed ID: 27602742
[No Abstract] [Full Text] [Related]
70. Priority pharmacogenetics for the African continent: focus on CYP450.
Alessandrini M; Pepper MS
Pharmacogenomics; 2014 Feb; 15(3):385-400. PubMed ID: 24533717
[TBL] [Abstract][Full Text] [Related]
71. Role of dermatology in pharmacogenomics: drug-induced skin injury.
Borroni RG
Pharmacogenomics; 2015; 16(4):401-12. PubMed ID: 25823788
[TBL] [Abstract][Full Text] [Related]
72. Progress and Challenges in Pharmacogenomics.
Van Driest SL; Cascorbi I
Clin Pharmacol Ther; 2021 Sep; 110(3):529-532. PubMed ID: 34412159
[No Abstract] [Full Text] [Related]
73. HLA-associated drug hypersensitivity and the prediction of adverse drug reactions.
Negrini S; Becquemont L
Pharmacogenomics; 2017 Oct; 18(15):1441-1457. PubMed ID: 29017379
[TBL] [Abstract][Full Text] [Related]
74. A review of pharmacogenetics of adverse drug reactions in elderly people.
Cardelli M; Marchegiani F; Corsonello A; Lattanzio F; Provinciali M
Drug Saf; 2012 Jan; 35 Suppl 1():3-20. PubMed ID: 23446782
[TBL] [Abstract][Full Text] [Related]
75. Identifying the prevalence of clinically actionable drug-gene interactions in a health system biorepository to guide pharmacogenetics implementation services.
Pasternak AL; Ward K; Irwin M; Okerberg C; Hayes D; Fritsche L; Zoellner S; Virzi J; Choe HM; Ellingrod V
Clin Transl Sci; 2023 Feb; 16(2):292-304. PubMed ID: 36510710
[TBL] [Abstract][Full Text] [Related]
76. The future of pharmacogenetics in the treatment of migraine.
Borro M; Guglielmetti M; Simmaco M; Martelletti P; Gentile G
Pharmacogenomics; 2019 Nov; 20(16):1159-1173. PubMed ID: 31637960
[TBL] [Abstract][Full Text] [Related]
77. Dosing recommendations for pharmacogenetic interactions related to drug metabolism.
Filipski KK; Pacanowski MA; Ramamoorthy A; Feero WG; Freedman AN
Pharmacogenet Genomics; 2016 Jul; 26(7):334-9. PubMed ID: 27058883
[TBL] [Abstract][Full Text] [Related]
78. Highly personalized reports for personalized drug selection by expert systems as clinical decision support.
Hizel HC
Per Med; 2017 Mar; 14(2):93-97. PubMed ID: 29754552
[No Abstract] [Full Text] [Related]
79. The phenotype standardization project: improving pharmacogenetic studies of serious adverse drug reactions.
Pirmohamed M; Aithal GP; Behr E; Daly A; Roden D
Clin Pharmacol Ther; 2011 Jun; 89(6):784-5. PubMed ID: 21593754
[TBL] [Abstract][Full Text] [Related]
80. Prescribing cascades in older adults.
Sternberg SA; Guy-Alfandary S; Rochon PA
CMAJ; 2021 Feb; 193(6):E215. PubMed ID: 33558408
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
